AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$UTHR

ROTHBLATT MARTINE A sold $4.7M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $493.46 ($477.70–$510.05, $4.69M total) across 24 trades on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale adds a modest bearish data point for traders, but the pre‑arranged nature tempers significance.

02

Market read

Primary source filing; provides new information on insider activity that could influence short‑term trading decisions.

03

What to watch

The 10b5‑1 plan indicates no discretionary timing; the sale may not reflect insider outlook on the business.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑09‑02

Background

Form 4 filing reveals insider transaction details for United Therapeutics.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $4.7M of United Therapeutics shares via a 10b5‑1 plan on 2026‑09‑02.

Expected impact

Potential modest dip in the near term as market digests the sale.

Evidence & confidence

C‑suite insider sale of ~9,500 shares (~0.3% of float) at $493 average price, disclosed in a Form 4, typically viewed as a bearish signal.

Market effects

Sector

May weigh on biotech/biopharma sector sentiment as insider sales are monitored.

Regional

Limited to U.S. markets where United Therapeutics trades.

Global

Minimal global impact beyond investors tracking the stock.

Counterpoint

What could challenge this read

The sale could be routine liquidity management under a pre‑arranged plan, not a negative signal.

Key entities

  • company
    United Therapeutics Corp

    Biopharma company listed on NASDAQ under ticker UTHR.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics, reporting the insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

SEP 10
$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min
SEP 9
$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min
SEP 9
$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min